Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients

INTRODUCTION: Disease-modifying treatments for Alzheimer's disease (AD) are likely to be offered only to patients with molecular evidence for Alzheimer pathology and expanded to patients with prodromal AD. We calculated the potential future costs of expanding the number of positron emission tom...

Descripción completa

Detalles Bibliográficos
Autores principales: Wittenberg, Raphael, Knapp, Martin, Karagiannidou, Maria, Dickson, John, Schott, Jonathan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709060/
https://www.ncbi.nlm.nih.gov/pubmed/31463360
http://dx.doi.org/10.1016/j.trci.2019.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709060/
https://www.ncbi.nlm.nih.gov/pubmed/31463360
http://dx.doi.org/10.1016/j.trci.2019.06.001

Ejemplares similares